FDA receives adverse event reports related to calcium gluconate infusions.
FDA has alerted healthcare professionals of possible contamination in calcium gluconate infusions produced by Specialty Compounding (Cedar Park, TX). The agency has received 15 adverse event reports by patients in two hospitals that received an infusion of calcium gluconate 2 grams in Sodium Chloride 0.9% for injection. The patients developed bacterial bloodstream infections caused by Rhodococcus equi, and it is believed that the infections arerelated to the infusions. Bacterial growth consistent with Rhodococcus equi was found in cultures taken from Specialty Compounding’s calcium gluconate.
FDA and the Centers for Disease Control and Prevention are working with Texas state officials to investigate the cause of the bacterial infections. FDA is asking healthcare professions to report adverse reactions to FDA’s MedWatch program.
Source: FDA.gov
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.